Treatment of AMO-1 cells with doxorubicin, another genotoxic compound that exerts at least part of its anti-myeloma effects via the p53 pathway, also showed a strong influence of the p53 status (Fig. 3c). This evidence concerns the gene TP53 and plasma cell myeloma.